{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:25:44Z","timestamp":1784903144213,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The gonadotrophin-releasing hormone (GnRH) antagonist protocol has some advantages, such as a simple method, short medication duration, and low incidence of ovarian hyperstimulation syndrome, but whether the GnRH antagonist protocol is suitable for normal ovarian responders has been controversial. We compared the clinical outcomes of fresh and frozen-thawed transfer cycles between the depot GnRH agonist protocol and GnRH antagonist protocol in normal ovarian responders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data of normal ovarian responders who underwent in vitro fertilization-embryo transfer (IVF-ET) or intracytoplasmic sperm injection-embryo transfer (ICSI-ET) between January 2017 and December 2018 in our hospital were retrospectively analysed. In this study, there were 1119 fresh transfer cycles, including 502 GnRH antagonist cycles (GnRH antagonist group) and 617 depot GnRH agonist cycles (depot GnRH agonist group), as well as 468 frozen-thawed transfer cycles, includng 191 GnRH antagonist cycles (GnRH antagonist group) and 277 depot GnRH agonist cycles (depot GnRH agonist group). The clinical outcomes were compared between the GnRH antagonist group and the depot GnRH agonist group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>With the fresh transfer cycles, there were no statistically significant differences in the anti-Mullerian hormone level, number of transferred embryos or high-quality embryo rate between the two groups. The total dosage of gonadotropin (Gn), duration of Gn stimulation, number of oocytes retrieved, clinical pregnancy rate and incidences of moderate and severe ovarian hyperstimulation syndrome (OHSS) were significantly lower but the abortion rate was significantly higher in the GnRH antagonist group than in the depot GnRH agonist group (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). With the frozen-thawed transfer cycles, there were no statistically significant differences in the number of transferred embryos, clinical pregnancy rate or abortion rate between the two groups (all <jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>With the fresh transfer cycles, the GnRH antagonist protocol had a lower clinical pregnancy rate and lower incidences of moderate and severe OHSS than the depot GnRH agonist protocol, but with the frozen-thawed transfer cycles, both protocols had similar clinical pregnancy rates. These results remain to be further confirmed through large-sample, prospective, randomized and controlled studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12884-021-03849-8","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T10:04:52Z","timestamp":1620727492000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Comparison of clinical outcomes between the depot gonadotrophin-releasing hormone agonist protocol and gonadotrophin-releasing hormone antagonist protocol in normal ovarian responders"],"prefix":"10.1186","volume":"21","author":[{"given":"Min","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"3849_CR1","first-page":"863","volume":"27","author":"Li","year":"2018","unstructured":"Li, Miao. Zhu Yi-min. Whether GnRH antagonist protocol is superior to GnRH agonist long protocol. J Reprod Med. 2018;27:863\u20136.","journal-title":"J Reprod Med"},{"key":"3849_CR2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.rbmo.2012.11.001","volume":"26","author":"R Orvieto","year":"2013","unstructured":"Orvieto R, Patrizio P. GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debate. Reprod Biomed Online. 2013;26:4\u20138.","journal-title":"Reprod Biomed Online"},{"key":"3849_CR3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4274\/tjod.03789","volume":"11","author":"ST Ceyhan","year":"2014","unstructured":"Ceyhan ST, Bayo\u011flu Tekin Y, Sakinci M, Ercan CM, Keskin U. What should be the protocol selection after failure of in-vitro fertilization at normoresponder patients: agonist or antagonist? Turk J Soc Obstet Gynecol. 2014;11:198\u2013202.","journal-title":"Turk J Soc Obstet Gynecol"},{"key":"3849_CR4","first-page":"1634","volume":"106","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2016","unstructured":"Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. FertilSteril. 2016;106:1634\u201347.","journal-title":"FertilSteril"},{"key":"3849_CR5","first-page":"196","volume-title":"Bourn Hall Clinic. A textbook of in vitro fertilization and assisted reproduction: the bourn hall guide to clinical and laboratory practice","author":"P Brinsden","year":"1999","unstructured":"Brinsden P. Bourn Hall Clinic. A textbook of in vitro fertilization and assisted reproduction: the bourn hall guide to clinical and laboratory practice. 2nd ed. New York: Parthenon Pub Group; 1999. p.\u00a0196.","edition":"2"},{"key":"3849_CR6","first-page":"128","volume":"38","author":"YAN Gui-min","year":"2017","unstructured":"Gui-min YAN, Yan-qiu WANG. Application of gonadotropin-releasing hormone antagonist in controlled ovarian hyperstimulation for patients with different ovarian function. J Tongji Univ. 2017;38:128\u201332.","journal-title":"J Tongji Univ"},{"key":"3849_CR7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.rbmo.2014.05.007","volume":"29","author":"D Grow","year":"2014","unstructured":"Grow D, Kawwass JF, Kulkarni AD, Durant T, Jamieson DJ, Macaluso M. GnRH agonist and GnRH antagonist protocols: comparison of outcomes among good-prognosis patients using national surveillance data. Reprod Biomed Online. 2014;29:299\u2013304.","journal-title":"Reprod Biomed Online"},{"key":"3849_CR8","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.fertnstert.2016.02.005","volume":"105","author":"C Alviggi","year":"2016","unstructured":"Alviggi C, Andersen CY, Buehler K, Giuseppe C, De Placido, Sandro C, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016;105:1452\u20133.","journal-title":"Fertil Steril"},{"key":"3849_CR9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/humrep\/deu266","volume":"30","author":"O Hamdine","year":"2015","unstructured":"Hamdine O, Eijkemans MJC, Len tjes EWG, Torrance HL, Macklon NS, Fauser BCJM, et al. Ov arian response prediction in GnRH antagonist treatment for IVF using anti-M\u00fcllerian hormone. Hum Reprod. 2015;30:170\u20138.","journal-title":"Hum Reprod"},{"key":"3849_CR10","doi-asserted-by":"crossref","unstructured":"Jun Gao,Yan-Wen Xu, Ben-Yu Miao,Can-Quan Zhou.Self-control study on reduced-dose depot versus daily administration of gonadotrophin-releasing congenital posterior polar cataracts in a Chinese family. BMC Ophthalmol\u00a02014;14:1\u20137.","DOI":"10.1111\/jog.12417"},{"key":"3849_CR11","first-page":"117","volume":"49","author":"Y Li","year":"2014","unstructured":"Li Y, Qiongfang Wu, Yingchun Yi. Effect of super -long down -regulation protocol on the outcome of IVF -ET in the infertile patients with PCOS. Jiangxi Med J. 2014;49:117\u201320.","journal-title":"Jiangxi Med J"},{"key":"3849_CR12","unstructured":"Min-feng S, Tie Zhou, Ying Wang, Guang-hua Chen, Ming Zhu, Jun Ou, et al. Revised super-longdown-regulation protocol improves the outcome of infertile patients with repeated implantation failure in IVF \/ ICSI-ET. J Reprod Contracept\u00a02014;25:89\u201396."},{"key":"3849_CR13","first-page":"650","volume":"9","author":"MF Ma","year":"2016","unstructured":"Ma MF, Li LB, Pei YQ, Cheng Z. Use of high-throughput targeted exome sequencing in Genetic diagnosis of Chinese family with congenital cataract. Int J Ophthalmol. 2016;9:650.","journal-title":"Int J Ophthalmol"},{"key":"3849_CR14","doi-asserted-by":"crossref","unstructured":"Jing Yang, Sheng Zhou, Minfei, Guo Y, Li, Jianjun Gu. Different alpha crystallin expression in human age-related and congenital cataract lens epithelium. BMC Ophthalmol. 2016;16:67\u201373.","DOI":"10.1186\/s12886-016-0241-1"},{"key":"3849_CR15","first-page":"2665","volume":"24","author":"Ding Mei-ling","year":"2018","unstructured":"Ding Mei-ling. Effects of different ovulation inducing schemes on pregnancy outcomes of infertile women with polycystic ovary syndrome. Int Med Health Guidance News. 2018;24:2665\u20138.","journal-title":"Int Med Health Guidance News"},{"key":"3849_CR16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.fertnstert.2010.06.068","volume":"95","author":"D Bodri\u00e3","year":"2011","unstructured":"Bodri\u00e3 D, Sunkara SK, Coomarasamy\u00e3 A. Gonadotropin-releasing hormone agonists versus antagonist for controlled ovarian hyperstimulation in oocyte donors:a systematic review and meta-analysis. Fertil Steril. 2011;95:164\u20139.","journal-title":"Fertil Steril"},{"key":"3849_CR17","unstructured":"Jin Lei Xu. Bei. Can GnRH antagonists replace agonists? J Reprod Med. 2015;24:778\u201382."},{"key":"3849_CR18","first-page":"219","volume":"38","author":"L Li Xuan","year":"2018","unstructured":"Li Xuan L, Jia-yin CWen-Sen, Wei D, Yun-dong Mao, Wei Wang. Comparison of long and antagonist regimens in normal response population. Chin J Reprod Contracep. 2018;38:219\u201323.","journal-title":"Chin J Reprod Contracep"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-021-03849-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-021-03849-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-021-03849-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T10:08:29Z","timestamp":1620727709000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-021-03849-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3849"],"URL":"https:\/\/doi.org\/10.1186\/s12884-021-03849-8","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"assertion":[{"value":"11 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was performed in accordance with the Declaration of Helsinki, and relevant guidelines and regulations. All study methods were also approved by the Institutional Review Board and Ethics Committee of the Women and Children\u2032 Hospital of Hubei Province [2016]IEC[BL003]. The written informed consent to participate in the study was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"372"}}